{"id":214931,"date":"2026-03-19T14:00:47","date_gmt":"2026-03-19T13:00:47","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=214931"},"modified":"2026-03-19T18:54:59","modified_gmt":"2026-03-19T17:54:59","slug":"curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/","title":{"rendered":"Curia expands Glasgow manufacturing capacity and enhances cell line development platform"},"content":{"rendered":"

Statement issued by the company (Announcement)<\/p>\n

\n

Curia<\/strong>, a leading contract research, development and manufacturing organization (CDMO)<\/strong>, today announced progress on the expansion at its Glasgow<\/strong>, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development.<\/p>\n

The Glasgow, UK, site is well known throughout the industry for its more than 25 years of experience with formulation, lyophilization development and sterile fill-finish capabilities, including ADCs and other highly potent products. The current expansion is expected to be completed by early 2027. The investment will add an Annex 1 compliant isolator-based vial filling line and lyophilizer. Once complete, Glasgow will be able to fill batches up to 20,000 vials and will be well\u2011positioned to support future small\u2011scale commercial fills.<\/p>\n

\u201cThis expansion in Glasgow comes as Curia is nearing completion of our significant expansion\u00a0in our commercial drug product facility in Albuquerque, NM,\u201d said Ron Aungst<\/strong>, VP, Drug Product Business Unit Operations. \u201cCuria has already secured crucial equipment with long lead times to help the Glasgow expansion project stay on track, and we do not anticipate any disruption to current operations during the expansion.\u201d<\/p>\n

Curia\u2019s clinical drug substance development capabilities have also been enhanced with improvements to the company\u2019s cell line development (CLD) platform. The CLD offering at Curia\u2019s Hopkinton, MA facility has been enhanced to incorporate IP-free semi-targeted integration technology that results in 6-fold higher titers compared to random integration technology. Curia\u2019s stable platform, CHO-GSN\u00ae, was derived from the same parental cell line as its transient platform, TunaCHO\u00ae, allowing partners to efficiently scale-up from discovery to GMP.<\/p>\n

\u201cOur biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-efficient and faster to advance partners through early-stage clinical manufacturing,\u201d said Jamie Grabowski<\/strong>, President, Research & Development. \u201cWith biotech-friendly licensing terms, reengineered cell line will be a critical component of successfully guiding partners on their path to commercialization.\u201d<\/p>\n

About Curia<\/h2>\n

Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients\u2019 lives. Visit us at curiaglobal.com<\/a>.<\/p>\n

Corporate Contact:\r\n<\/strong>Viana Bhagan\r\nCuria\r\n+1 518 512 2111\r\ncorporatecommunications@CuriaGlobal.com<\/a><\/pre>\n
AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Statement issued by the company (Announcement) Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility […]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[125518],"tags":[],"class_list":["post-214931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"\nCuria expands Glasgow manufacturing capacity<\/title>\n<meta name=\"description\" content=\"Curia, a leading CDMO, announced progress on the expansion at its Glasgow, UK sterile drug product facility.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curia expands Glasgow manufacturing capacity","description":"Curia, a leading CDMO, announced progress on the expansion at its Glasgow, UK sterile drug product facility.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Curia expands Glasgow manufacturing capacity and enhances cell line development platform","datePublished":"2026-03-19T13:00:47+00:00","dateModified":"2026-03-19T17:54:59+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/"},"wordCount":502,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/","url":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/","name":"Curia expands Glasgow manufacturing capacity","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-03-19T13:00:47+00:00","dateModified":"2026-03-19T17:54:59+00:00","description":"Curia, a leading CDMO, announced progress on the expansion at its Glasgow, UK sterile drug product facility.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/curia-expands-glasgow-manufacturing-capacity-and-enhances-cell-line-development-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Curia expands Glasgow manufacturing capacity and enhances cell line development platform"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-TUD","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/214931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=214931"}],"version-history":[{"count":4,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/214931\/revisions"}],"predecessor-version":[{"id":215013,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/214931\/revisions\/215013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=214931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=214931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=214931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}